Banco Santander S.A. Takes Position in Cencora, Inc. (NYSE:COR)

Banco Santander S.A. purchased a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,655 shares of the company’s stock, valued at approximately $821,000.

A number of other institutional investors and hedge funds also recently modified their holdings of COR. Hickory Asset Management Inc. bought a new stake in Cencora in the fourth quarter valued at approximately $572,000. Sylvest Advisors LLC bought a new stake in shares of Cencora in the 4th quarter valued at $1,105,000. Insight Wealth Strategies LLC increased its position in shares of Cencora by 124.6% in the 4th quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock valued at $4,549,000 after buying an additional 11,232 shares in the last quarter. Cerity Partners LLC increased its position in shares of Cencora by 10.1% in the 3rd quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock valued at $8,881,000 after buying an additional 3,610 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its holdings in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company’s stock worth $1,403,000 after acquiring an additional 1,995 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Up 0.3 %

Cencora stock opened at $254.54 on Monday. The company has a market cap of $49.36 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a fifty day simple moving average of $244.34 and a 200 day simple moving average of $238.39. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. Cencora’s dividend payout ratio is 31.29%.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,648 shares of company stock valued at $2,862,342. 10.80% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Wells Fargo & Company increased their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Finally, StockNews.com downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.